CCL22 and myeloid sarcoma: A recent study examining these concepts in MS brain tissue defined CD40, CD74 and C–X–C chemokine ligand CXCL10 as markers of M1 activation, and CCL22 and CD209 (DC-SIGN) as M2a markers [21].